Page 171 - 2021_07-Haematologica-web

Real-world CNS outcomes in Burkitt lymphoma
Verastem, Affimed and Bayer; and has received honoraria from and sat on a DMC for Pharmacyclics. AD has received research funding from Aptose Biosciences, Gilead Sciences, Takeda Oncology and Bristol-Myers Squibb; has received research fund- ing and provided consultancy services for AstraZeneca, Genentech, Bayer Oncology and Verastem Oncology; has acted as a consult- ant for Beigene. TG Therapeutics, Celgene, Nurix and Rigel Pharmaceuticals; and is a Leukemia and Lymphoma Society Scholar in Clinical Research. SDS has received research funding from Incyte Corporation, Seattle Genetics, Portola Pharmaceuticals, Pharmacyclics, Acerta Pharma BV, Genentech and Denovo Biopharma; he has received research funding from and acted as a consultant for Merck Sharp & Dohme Corp; and he has been a member of Astra Zeneca’s Board of Directors or advisory committees and has received research funding from this company; a Astra Zeneca. An immediate family member has received research funding from Ignyta, Bristol-Myers Squibb and Ayala. SN has provided advisory board services for Celgene and Sanofi. NR has acted as a consultant for KITE Pharma, Abbvie and Celgene; has received research funding from Genentech; and has provided consultancy services for and received research funding from BMS. UF has received honoraria from Celgene and research funding from Kite Pharma. NE has received honoraria from Pharmacyclics and taken part in a speakers bureau for Verastem Oncology. NK has been a member of the Board of Directors or an advisory committee of Seattle Genetics and Abbvie; has received research funds from Bristol Myers; and has delivered educational content or symposia for Janssen. JPA has received honoraria from Targeted Oncology; and acted as a consultant for OncLive. An immediate family member has had contacts with Puma Biotechnology, Agios, Inovio Pharmaceuticals and Foundation Medicine. MSY has received honoraria from Bayer; has received research funding from Genentech; and has acted as a consultant for Octapharma and Abbvie. CD has received research funding from Denovo, Incyte, LAM Therapeutics, MEI, Millenium/Takeda and Trillium; and has acted as consultant for and received research funding from Bristol-Myers Squibb, Genentech, Merck and Seattle Genetics. RK has sat on speakers’ bureaus for Takeda, AstraZeneca and BeiGene; has supplied advisory board services
for Karyopharm; and has sat on speakers’ bureaus and advisory boards and received research support from Kite, Gilead, BMS, Celgene and Juno. PM has acted as a consultant for Celgene, Teneobio, Karyopharm, Janssen, Sandoz and I-MAB. GM has participated in speakers’ bureaus for Tevan Oncology. MK has acted as a consultant for Pharmacyclics, AstraZeneca and Celgene; has sat on speakers’ bureaus for Seattle Genetics; and is an employee of the University of Colorado. ML has acted as a con- sultant for Spectrum, Seattle Genetics, Portola, OncLive, Novartis. Kite, Gilead Sciences, Inc., DAVA, Bayer, AbbVie, VANIUM and Verastem; has received research funding from MiRagen and Curis; and has acted as a consultant for and received research funding from TG Therapeutics, Juno Therapeutics and Janssen Scientific Affairs, LLC. CP has received research funding from Xencor, Roche/Genentech, Infinity, TG Therapeutics, AbbVie and Acerta/AstraZeneca; has acted as a consultant for Pharmacyclics, Janssen, Amgen and Bayer, and has provide consultancy services for and received research funding from Genentech, BeiGene and Kite. ISL has been a member of the Board of Directors or an advi- sory committee of Janssen Scientific and Seattle Genetics; and has received research funding from the NIH. AJO has received research funding from Genentech, Adaptive Biotechnologies, TG Therapeutics and Spectrum Pharmaceuticals. The remaining authors report no significant conflicts of interest.
Contributions
ASZ, AME, ISL and AJO designed the research, performed the analysis, and wrote the manuscript draft. ASZ and AME contributed equally. AD, SDS, DJ, LAL, CW, S-HK, SN, SSu, NR, UF, VPK, NE, KAB, NK, DS, JPA, AG, SY, CD, ER, GV, RK, YS, AT, MB, PM, SSt, AC, YKC, AS-E, AK, MCC, KMB, SB, BMH, VMO-N, CD'A, DAB, SMM, RV, GM, AS, MJG, KAD, MS, PC, MK, MAL, NP, PV, CAP, VB and TP contributed patients’ data, and edited and approved the man- uscript.
Funding
This work was conducted with voluntary support of the con- tributing institutions and researchers, without any external funding.
References
1.Zayac AS, Olszewski AJ. Burkitt lym- phoma: bridging the gap between advances in molecular biology and therapy. Leuk Lymphoma. 2020;61(8):1784-1796.
2. Sariban E, Edwards B, Janus C, Magrath I. Central nervous system involvement in American Burkitt's lymphoma. J Clin Oncol. 1983;1(11):677-681.
3.Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nerv- ous system recurrence in aggressive lym- phoma--a survey of 1693 patients treated in protocols of the German High-Grade Non- Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149- 157.
4. Oosten LEM, Chamuleau MED, Thielen FW, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective com- parison of four treatment regimens. Ann Hematol. 2018;97(2):255-266.
5. Jakobsen LH, Ellin F, Smeland KB, et al. Minimal relapse risk and early normaliza- tion of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. Br J
Haematol. 2020;189(4):661-671.
6.Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin
Oncol. 1999;17(8):2461-2470.
7. Woessmann W, Zimmermann M,
Meinhardt A, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135(14):1124-1132.
8.Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-1580.
9.Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemothera- py with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165(1):102-111.
magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45(4):761-767.
12. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915-1925.
13. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519-2529.
14.AlderuccioJP,LossosIS.DA-EPOCH-Rfor adult Burkitt's lymphoma: pros and cons. J Oncol Pract. 2018;14(11):676-678.
15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): B-cell lymphomas. Version 4.2020 - August 13, 2020. Available from: https://www.nccn.org/professionals/physi- cian_gls/pdf/b-cell.pdf.
16. Evens AM, Danilov AV, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real world outcomes and prognostication across 30 US cancer centers. Blood. 2021;137 (3):374-386.
17. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health
10.
Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a ran- domised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10036):2402-2411.
11.LacasceA,HowardO,LibS,etal.Modified
haematologica | 2021; 106(7)
1941